Smith, David C.
Kroiss, Matthias
Kebebew, Electron
Habra, Mouhammed Amir
Chugh, Rashmi
Schneider, Bryan J.
Fassnacht, Martin
Jafarinasabian, Pegah
Ijzerman, M. Marian
Lin, Vivian H.
Mohideen, Pharis
Naing, Aung
Funding for this research was provided by:
Millendo Therapeutics, Inc. (MDACC-600850-90-100300-55-MDGRN-00000946-1111)
Article History
Received: 2 December 2019
Accepted: 15 January 2020
First Online: 27 January 2020
Compliance with ethical standards
:
: David C. Smith received research funding for this project from Millendo Therapeutics, formerly Atterocor. David C. Smith received research funding from Bayer, Bristol-Myers Squibb (Medarex), Eli Lilly, Genentech, Astellas, MedImmune, Seattle Genetics, Millenium, Incyte, Novartis, F. Hoffman-La Roche, ESSA, and OncoMed. Matthias Kroiss received research support from Ipsen. Electron Kebebew declares no conflict of interest. Mouhammed Amir Habra received research funding from Exelixis. Mouhammed Amir Habra is a consultant and on the advisory board of Corcept Therapeutics and HRA Pharma. Rashmi Chugh declares no conflict of interest. Bryan J. Schneider received institutional research funding from Incyte, Genentech and Bristol-Meyers Squibb. Martin Fassnacht declares no conflict of interest. Pegah Jafarinasabian is a former employee of Millendo Therapeutics. M. Marian Ijzerman is a current employee of Millendo Therapeutics. Vivian H. Lin is a current employee of Millendo Therapeutics. Pharis Mohideen is a former employee of Millendo Therapeutics and currently owns shares in Millendo Therapeutics. Aung Naing received research funding from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Meyers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera BioSciences, TopAlliance BioSciences, Eli Lilly, Kymab, PsiOxus, and Immune Deficiency Foundation (spouse). Aung Naing is on the advisory board for CytomX Therapeutics and Novartis and received reimbursement for travel and accommodation from ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.